Evidence map›Paper›PMID 24934618›Full record

ArticleCancer prevention research (Philadelphia, Pa.)2014

Laboratory to community: chemoprevention is the answer.

Kenneth Olden, Suryanarayana V Vulimiri

Abstract readComment
PubMed Publisher
In one paragraph

Article in Cancer prevention research (Philadelphia, Pa.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Retrospective and Prospective Look at Aflatoxin Research and Development from a Practical Standpoint.International journal of environmental research and public health · 2019
    Article
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Kenneth OldenAuthors' Affiliation: National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Washington, District of Columbia olden.kenneth@epa.gov.
Suryanarayana V VulimiriAuthors' Affiliation: National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Washington, District of Columbia.
Environmental Protection Agency · USNational Center for Environmental Assessment (EPA) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the current issue, Johnson and colleagues present exciting results, using biomarkers involved in aflatoxin B1 (AFB1)-induced hepatocarcinogenesis, as an example of a conceptual framework to target mechanisms of action in developing chemopreventive agents. Their innovative approach offers considerable promise for a field that has long been neglected. Proof-of-principle was demonstrated using a synthetic triterpenoid (CDDO-Im), which activates Nrf2 signal transduction pathway, inhibits formation of AFB1-induced DNA adducts and neoplastic hepatic foci, and alters the expression of genes associated with aflatoxin-mediated toxicity.

Indexed as

Aflatoxin B1AnimalsBiomarkers, TumorCarcinoma, HepatocellularDNA AdductsGene Expression Regulation, NeoplasticGlutathione S-Transferase piImidazolesLiver Neoplasms, ExperimentalMaleOleanolic Acid1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazoleAflatoxin B1aflatoxin B1-DNA adductBiomarkers, TumorDNA AdductsGlutathione S-Transferase piGstp1 protein, ratImidazolesOleanolic Acid

Identifiers

PMID24934618
OpenAlexW2104851327

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.